Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008

This study has been completed.
Sponsor:
Information provided by:
NanoBio Corporation
ClinicalTrials.gov Identifier:
NCT01333462
First received: April 5, 2011
Last updated: April 11, 2011
Last verified: April 2011
  Purpose

The purpose of this study is to test the safety and immune response of a new intranasal vaccine against influenza, called NB-1008. The vaccine is composed of a licensed vaccine that is normally given as an injection, called Fluzone, and an adjuvant (additive that helps a vaccine work better), called W805EC.


Condition Intervention Phase
Healthy Adult Volunteers
Biological: NB-1008
Other: Control
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1 Randomized, Single-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 (Fluzone® + 60%W805EC) in Healthy Adult Volunteers

Resource links provided by NLM:


Further study details as provided by NanoBio Corporation:

Primary Outcome Measures:
  • Number of Participants with Adverse Events [ Time Frame: 365 Days ] [ Designated as safety issue: Yes ]
    Adverse events (AE) collected through Day 28 and Serious Adverse Events (SAE) collected through Day 365.


Secondary Outcome Measures:
  • Serum hemagglutination-inhibition (HAI) Geometric Mean Titer (GMT) and proportion of Volunteers with >=4 fold increase in titer as well as proportion of volunteers with titer >= protective level of 40 [ Time Frame: Day 28 and Day 60 ] [ Designated as safety issue: No ]
    HAI antibody titers to H1N1, H3N2, and B influenza strains contained in the vaccine.

  • Nasal wash anti-Fluzone IgA Geometric Mean Titer (GMT) and proportion of volunteers with >=4 fold increase in GMT anti-Fluuzone IgA titer [ Time Frame: Day 28 and Day 60 ] [ Designated as safety issue: No ]
    Nasal Wash IgA to Fluzone.


Enrollment: 199
Study Start Date: March 2009
Study Completion Date: September 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Phosphate Buffered Saline (PBS) IN Other: Control
The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Active Comparator: Fluzone 4 mcg HA IN Other: Control
The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Active Comparator: Fluzone 15 mcg HA IM Other: Control
The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Experimental: NB-1008 4 mcg HA 5% W805EC Biological: NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Experimental: NB-1008 4 mcg HA 10% W805EC Biological: NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Experimental: NB-1008 4 mcg HA 15% W805EC Biological: NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Experimental: NB-1008 4 mcg HA 20% W805EC Biological: NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Active Comparator: Fluzone 10 mcg HA IN Other: Control
The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Experimental: NB-1008 10 mcg HA 5% W805EC Biological: NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Experimental: NB-1008 10 mcg HA 10% W805EC Biological: NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Experimental: NB-1008 10 mcg HA 15% W805EC Biological: NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Experimental: NB-1008 10 mcg HA 20% W805EC Biological: NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

  Eligibility

Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female.
  2. Are 18-49 years of age, inclusive.
  3. If female, must be non-pregnant as confirmed by a negative serum pregnancy test conducted at screening and a negative urine pregnancy test conducted at the site within 24 hours preceding receipt of vaccine.
  4. Females who are not surgically sterile or at least one year post-menopausal agree to use oral, implantable, transdermal or injectable contraceptive or another reliable form of contraception approved by the Investigator for a minimum of 30 days prior to vaccination and for 3 months following vaccination.
  5. Healthy, as determined by medical history, physical examination, vital signs, and clinical laboratory examinations.
  6. Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.
  7. Has given written informed consent to participate in the study.

Exclusion Criteria:

  1. Presence of significant acute or chronic, uncontrolled medical or psychiatric illness (institution of new medical or surgical treatment, or a significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months). Subjects with a history of chronic cough, frequent sinus infections, sinusitis, allergic rhinitis, nasal polyps or obstruction, including deviated septum significant enough to obstruct the nasal openings are to be excluded. Subjects with seasonal rhinitis may be included if their 'season' does not occur within 3 months of the vaccination date and they are not currently receiving intranasal steroids.
  2. Receipt of the 2008-2009 influenza vaccine.
  3. Positive serology for HIV-1 or HIV-2, or HCV antibodies.
  4. Platelet count <150,000/mm3.
  5. Positive urine drug screen.
  6. History of aspiration, dysphagia, swallowing disorders, stroke or other neurologic conditions that may predispose the subject to aspiration of test articles into the respiratory tract.
  7. History of Bell's palsy.
  8. Cancer or treatment for cancer, within 3 years. Subjects with a history of cancer who are disease-free without treatment for 3 years or more are eligible. Basal cell carcinoma (BCC) or (SCC) are allowed, unless present on or near the nose.
  9. Impaired immune responsiveness, regardless of cause, including diabetes mellitus.
  10. Presently receiving or history of receiving any medications or treatments that affects the immune system such as immune globulin, interferon, immunomodulators, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable) in the past 6 months.
  11. Chronic use of inhaled or intranasal sprays including decongestants and corticosteroids.
  12. Presently a smoker or tobacco user or have a history of smoking or tobacco use within the past year prior to screening.
  13. Receipt or planned administration of a nonstudy vaccine within 30 days before the study, including licensed influenza vaccines and prior to the Day 60 telephone contact. Immunization on an emergency basis with Tetanus Toxoids Adsorbed for adult use (Td or Tdap) up to 8 days before or at least 8 days after a dose of study vaccine will be allowed. Administration of study vaccine can be delayed if a nonstudy vaccine has been administered and will be given as soon as acceptable, as described above.
  14. Known allergy to any vaccine component, including eggs, egg products, or thimerosal.
  15. History of allergic and/or anaphylactic type reaction to injected vaccines or to any of the components of NB-1008 [soybean oil, dehydrated alcohol (anhydrous ethanol), polysorbate (Tween 80) and cetylpyridinium chloride (CPC)].
  16. History of drug or chemical abuse in the year before the study.
  17. Receipt of any investigational product or nonregistered drug within the 30 days before study entry or currently enrolled in any investigational drug study or intends to enroll in such a study within the ensuing 6 month period.
  18. Use of nasally administered prescription or over-the-counter (OTC) medications within 7 days before vaccination
  19. Receipt of blood or blood products 8 weeks before study entry or planned administration prior to the Day 60 telephone contact.
  20. Donation of blood or blood products within 8 weeks before study entry or at any time up to the Day 28 clinic visit.
  21. Acute disease within a week prior to vaccination, defined as the presence of a moderate or severe illness (as determined by the investigator through medical history and physical examination) with or without fever. For subjects with a minor illness, such as diarrhea, or mild upper respiratory tract infection with or without low-grade febrile illness, the subject can be re-screened once they have complexly recovered.
  22. Any condition that, in the opinion of the investigator, might interfere with study objectives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01333462

Locations
United States, Kansas
Johnson County Clin-Trials
Lenexa, Kansas, United States, 66219
Sponsors and Collaborators
NanoBio Corporation
  More Information

No publications provided

Responsible Party: Jakub Simon, MD, MS/ Director, Clinical Vaccine Development, NanoBio Corporation
ClinicalTrials.gov Identifier: NCT01333462     History of Changes
Other Study ID Numbers: NB-1008-001
Study First Received: April 5, 2011
Last Updated: April 11, 2011
Health Authority: United States: Food and Drug Administration

ClinicalTrials.gov processed this record on August 01, 2014